10 completed, 1 terminated. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 10, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow adacel: new trials by email Literature Review of adacel trials Research Report on adacel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tdap Vaccine Safety for Plasma Donors Adacel - Tetanus | Phase 2 / Phase 3 | Completed | GCAM Inc. | 110 | 2020-02-03 | 2022-12-06 |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed, Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 688 | 2016-12-19 | 2022-03-25 |
| Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, Diphtheria and Tetanus toxoids adsorbed - Tetanus, Diphtheria | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 534 | 2014-03-01 | 2017-05-30 |
| Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL), DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed), Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed) - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1440 | 2013-11-01 | 2015-05-19 |
| Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Disease | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2012-07-01 | 2013-12-03 |
| A Study to Assess the Safety of Adacel® Vaccine Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis) - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 30 | 2009-12-01 | 2016-05-16 |
| Pertussis Maternal Immunization Study Tdap, Td - Pregnant Women | Phase 2 / Phase 3 | Completed | Scott Halperin | 320 | 2007-11-01 | 2020-08-27 |
| Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 Taking of blood samples, Boostrix, Adacel - Acellular Pertussis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 1954 | 2007-06-01 | 2020-05-01 |
| Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) - Tetanus, Diphtheria | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1045 | 2007-04-01 | 2014-02-07 |
| Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years Boostrix™, ADACEL® - Acellular Pertussis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 2337 | 2006-07-13 | 2018-08-07 |
| Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan Diphteria, tetanus, and Acellular Pertussis vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 115 | 2005-11-01 | 2016-04-14 |
Tetanus (8) · Diphtheria (7) · Whooping Cough (7) · Dengue (1) · Meningitis (1) · Meningococcal Infections (1) · Severe Dengue (1)
Sanofi Pasteur, a Sanofi Company (7) · GlaxoSmithKline (2) · GCAM Inc. (1) · Scott Halperin (1)
United States (4) · Canada (2) · China (1) · Japan (1) · Philippines (1) · South Korea (1) · Taiwan (1) · Vietnam (1)
PMID 21945698, PMID 30010773, PMID 34117198, PMID 38461048
2019 (1)